# Report Quality Review: NSCLC Dual-Target Drug Candidates

**Report**: `/home/donbr/ai2026/lifesciences-deepagents/output/cqs/nsclc-dual-target-drug-candidates-report.md`

**Competency Question**: "What specific drug candidates demonstrate efficacy in targeting both mutant and wild type cells with high efficiency for NSCLC (Non-Small Cell Lung Cancer), a known research interest?"

**Verdict: PARTIAL**

The report is well-structured and clinically sophisticated, following the Fuzzy-to-Fact protocol phases correctly and producing a comprehensive answer to the competency question. However, it has notable gaps in source attribution, evidence grading granularity, and some claims that likely derive from training knowledge rather than tool output. Below are the 10 dimension evaluations.

---

## 1. CURIE Resolution -- PASS (with minor issues)

**Genes**: All three driver genes are resolved to canonical CURIEs with full provenance:
- EGFR: `HGNC:3236`, Ensembl `ENSG00000146648` -- cited `hgnc_search_genes("EGFR")` and `hgnc_get_gene("HGNC:3236")`
- KRAS: `HGNC:6407`, Ensembl `ENSG00000133703` -- cited
- ALK: `HGNC:427`, Ensembl `ENSG00000171094` -- cited

**Proteins**: UniProt IDs resolved for all three (P00533, P01116, Q9UM73) with `uniprot_get_protein` citations.

**Compounds**: All 24 drugs have ChEMBL IDs (e.g., `CHEMBL3353410` for Osimertinib). These appear in the correct bare format for API arguments and are consistently presented.

**Disease**: `EFO_0003060` is stated on line 5 and `EFO:0003060` in the knowledge graph section (line 201). Note the inconsistent format: `EFO_0003060` (underscore) vs `EFO:0003060` (colon). The graph-builder skill specifies colon-separated CURIEs (`EFO:0000574`). The underscore variant on line 5 is the raw Open Targets format, while the colon variant is the Graphiti CURIE convention. This is a minor inconsistency but not a failure.

**Missing**: No MONDO CURIE is provided for NSCLC. The skill's CURIE conventions list both `EFO:` and `MONDO:` as valid disease prefixes. The report uses only EFO, which is acceptable since Open Targets uses EFO natively.

**ChEMBL target IDs** in the validation table (line 179: `CHEMBL:CHEMBL203`, `CHEMBL:CHEMBL2189121`, `CHEMBL:CHEMBL4247`) use a redundant `CHEMBL:CHEMBL` prefix. The skill convention is `CHEMBL:203` (prefix + local ID), not `CHEMBL:CHEMBL203`. This is a formatting error in 3 entries.

**Score: 8/10** -- All entities resolved; minor CURIE format inconsistencies (EFO underscore vs colon, double-CHEMBL prefix).

---

## 2. Source Attribution -- PARTIAL FAIL

**Sourced claims**: The report includes inline source citations for:
- Gene resolution (Phase 1): 4 entities, all cited with `[Source: hgnc_search_genes(...)]` and `[Source: hgnc_get_gene(...)]`
- Protein enrichment (Phase 2): 3 UniProt citations -- `[Source: uniprot_get_protein("UniProtKB:P00533")]` etc.
- Disease association (Phase 1): `[Source: opentargets_get_associations(ENSG00000146648)]`
- Drug discovery (Phase 4a): 3 citations to `Open Targets GraphQL knownDrugs(ENSG...)` -- one per drug class
- Trial validation (Phase 4b/5): 3 NCT IDs each cited with `[Source: clinicaltrials_get_trial("NCT:...")]`
- Trial search counts (lines 138, 149, 159): "328 NSCLC trials for Osimertinib", "34 NSCLC trials for Sotorasib", "52 NSCLC trials for Lorlatinib" -- these counts are NOT cited with a source tool call

**Unsourced claims** (significant):
- **Line 43**: "Activating mutations (exon 19 deletions, L858R) drive ~15% of NSCLC" -- no source citation. This is epidemiological knowledge likely from training data.
- **Line 48**: "G12C mutation (~13% of NSCLC) was historically undruggable until covalent inhibitors (2021)" -- no source citation. Training knowledge.
- **Line 53**: "EML4-ALK fusion (~5% of NSCLC)" -- no source citation.
- **Lines 85-87**: Dual-target evidence section for EGFR (covalent C797 binding, 10-100x potency) -- no tool citations.
- **Lines 103-105**: KRAS monoallelic claim, >100x selectivity -- no tool citations.
- **Lines 128-131**: ALK dual-target evidence (neuroblastoma models, Cmax claims, multi-kinase profile) -- no tool citations.
- **Lines 220-225**: The entire "Why Both Mutant and Wild-Type?" discussion section has zero source citations.
- **Lines 229-234**: Drug classes dual-activity table (selectivity ratios like "10-100x", ">100x") -- no sources.
- **Lines 238-241**: FLAURA trial (18.9-month PFS), CodeBreaK 100 (37.1% ORR), CROWN trial (78% 5-year PFS) -- **these are specific trial outcome numbers with no tool citations**. Line 242 explicitly acknowledges: "Pivotal trial data (not included in tool outputs but referenced in FDA approvals)".
- **Lines 266-272**: Clinical recommendations table -- no tool sources.
- **Lines 276-278**: Limitations section -- statements about toxicity, resistance mechanisms, biomarker gaps -- no sources.

**Count**: Approximately 18-20 distinct factual claims are sourced (Phases 1, 2, 4a drug lists, 4b/5 trial validation). Approximately 15-18 distinct factual claims lack source citations, concentrated in the Discussion, Dual-Target Evidence subsections, and Clinical Recommendations. The report itself admits on line 242 that some data came from outside tool outputs.

**Score: 4/10** -- The structured Phase sections have good attribution, but the Discussion and dual-target evidence sections rely heavily on unsourced claims. The reporting skill requires `[Source: tool(param)]` on **every factual claim**.

---

## 3. LOCATE then RETRIEVE Discipline -- PASS

The report shows clear LOCATE-then-RETRIEVE patterns:
- **Genes**: `hgnc_search_genes("EGFR")` (LOCATE) followed by `hgnc_get_gene("HGNC:3236")` (RETRIEVE) -- lines 29-31
- **Proteins**: UniProt IDs obtained from HGNC cross-references (LOCATE via HGNC), then `uniprot_get_protein("UniProtKB:P00533")` (RETRIEVE) -- lines 41, 47, 52
- **Disease associations**: `opentargets_get_associations(ENSG00000146648)` (RETRIEVE using Ensembl ID from HGNC) -- line 28, 42
- **Drugs**: Open Targets GraphQL `knownDrugs` using Ensembl IDs from Phase 2 -- lines 63, 95, 115
- **Trials**: `clinicaltrials_get_trial("NCT:03804580")` (RETRIEVE) -- lines 142, 152, 163

The chain is intact: HGNC (gene CURIE) -> UniProt (protein function) -> Ensembl ID (for Open Targets) -> knownDrugs (drug discovery) -> ClinicalTrials.gov (trial validation). No entity appears to have been invented without a prior LOCATE step.

**Score: 9/10** -- Strong LOCATE->RETRIEVE chain throughout the structured phases.

---

## 4. Disease CURIE in ENRICH Phase -- PASS

The disease CURIE `EFO_0003060` appears at the top of the report (line 5) in the Disease Context field, and the ANCHOR phase (line 28) shows it was resolved via `opentargets_get_associations(ENSG00000146648)`. The NSCLC association score of 0.85 is stated (line 42), indicating the disease was identified from Open Targets association data using the EGFR Ensembl ID.

The disease CURIE is then used in Phase 6 as the disease hub node (`EFO:0003060`, line 201).

**Score: 8/10** -- Disease CURIE resolved early and used downstream. Minor: it appears in Phase 1 (ANCHOR) rather than Phase 2 (ENRICH) as the skill prescribes, but it is resolved via Open Targets which is acceptable.

---

## 5. Open Targets Pagination -- PASS

The report references "Open Targets GraphQL knownDrugs" three times (lines 63, 95, 115), once per drug class (EGFR, KRAS, ALK). There is no mention of pagination failures or errors. The drug lists returned (16, 2, and 7 drugs respectively) are within reasonable `size` parameter bounds.

The skill specifies: "Use `size` parameter only... Do NOT use `page` or `index`". The report does not mention any pagination issues, suggesting the `size`-only pattern was followed or pagination was not needed (the largest result set is 16 drugs, well within a `size: 25` query).

The MEMORY.md notes that "first query failed (pagination), second succeeded" for a prior FOP analysis, but no such issue is reported here.

**Score: 8/10** -- No pagination failures reported; drug counts are consistent with single-page queries.

---

## 6. Evidence Grading -- PARTIAL FAIL

**Present**: The report includes evidence grades at the end of each phase section:
- Phase 1 (ANCHOR): "L4 (Clinical)" -- line 33
- Phase 2 (ENRICH): "L3 (Multi-DB)" -- line 55
- Phase 4a EGFR: "L4 (Clinical)" -- line 89
- Phase 4a KRAS: "L4 (Clinical)" -- line 109
- Phase 4a ALK: "L4 (Clinical)" -- line 132
- Phase 4b (TRAVERSE_TRIALS): "L4 (Clinical)" -- line 169
- Phase 5 (VALIDATE): "L4 (Clinical)" -- line 191
- Discussion: "L4 (Clinical)" -- line 242
- Overall: "Median Evidence Grade: L4 (Clinical), Confidence Score: 9.5/10" -- lines 290-292

**Issues**:
1. **No claim-level grading**: The reporting skill requires grading **each claim individually** (see "Grading Procedure" in the skill). The report only provides section-level grades. There are no individual claim scores, no modifier calculations, no score ranges.
2. **Inflated confidence**: The overall score of 9.5/10 is extremely high given that ~15+ claims are unsourced (see Dimension 2). The reporting skill warns about "Inflated Confidence" specifically: "A single-database claim is L1 regardless of how 'well known' the relationship seems."
3. **Discussion section graded L4**: Line 242 grades the pivotal trial data (FLAURA, CodeBreaK 100, CROWN) as L4 but simultaneously admits these data were "not included in tool outputs." This contradicts the grading criteria, which require tool-based evidence for scoring.
4. **Missing median calculation**: The skill requires "median of all claim scores" with a "range (lowest to highest claim score)." The report provides no range and no individual scores to compute a median from.
5. **Downgrade factors acknowledged but insufficient**: Lines 300-302 note -0.5 for missing RCT data, but the much larger issue of unsourced claims in the Discussion is not addressed.

**Score: 4/10** -- Evidence levels are present but applied at section level, not claim level. The 9.5/10 confidence is not justified given the unsourced claims. The grading procedure from the reporting skill was not followed.

---

## 7. Gain-of-Function Filter -- PASS

This dimension is relevant because NSCLC involves gain-of-function mutations in EGFR (activating mutations like L858R, exon 19 deletions), KRAS (G12C is a constitutively active GTPase), and ALK (EML4-ALK fusion causes constitutive kinase activation). All three are gain-of-function alterations.

The report correctly includes only **inhibitors and antagonists**:
- EGFR: All 16 drugs are inhibitors (TKIs) or blocking monoclonal antibodies -- appropriate for gain-of-function
- KRAS: Both drugs are inhibitors (covalent G12C-specific) -- appropriate
- ALK: All 7 drugs are tyrosine kinase inhibitors -- appropriate

No agonists or activators appear in any drug table. The mechanisms listed ("inhibitor", "mAb blocking ligand binding", "covalent C797 binding", "locking KRAS G12C in inactive GDP-bound state") are all inhibitory.

**Score: 10/10** -- Agonists correctly excluded from all drug classes.

---

## 8. Clinical Trial Validation -- PASS (with caveats)

Three NCT IDs are presented and validated:
- `NCT:03804580` (Osimertinib, EGFR+ NSCLC) -- Status: ACTIVE_NOT_RECRUITING, cited with `[Source: clinicaltrials_get_trial("NCT:03804580")]`
- `NCT:06249282` (Sotorasib + Carfilzomib, KRAS G12C NSCLC) -- Status: RECRUITING, cited
- `NCT:04362072` (Lorlatinib, ALK+ NSCLC) -- Status: COMPLETED, cited

All three are marked as verified in the Phase 5 validation table (lines 185-189) with check marks and source citations.

**Caveats**:
1. The NCT ID format uses `NCT:` prefix (colon-separated), while the skill convention specifies bare `NCT03312634` (no prefix). This is inconsistent with the skill's CURIE conventions: "NCT03312634 for trials (no prefix needed -- NCT is the standard)."
2. Only 3 trials are validated out of "414+ clinical trials" mentioned in the executive summary. The 414 number is a sum of search result counts (328 + 34 + 52) and represents the landscape, not individually validated trials. This is acceptable -- the report selects representative trials -- but the executive summary's "414+" phrasing could imply all were validated.
3. The trial detail data (design, eligibility, primary outcomes) for each of the 3 trials is comprehensive, suggesting actual `clinicaltrials_get_trial` retrieval.

**Score: 7/10** -- NCT IDs present and verified via tool calls; minor format inconsistency; only 3 of the mentioned landscape validated individually.

---

## 9. Completeness -- PASS

The competency question asks: "What specific drug candidates demonstrate efficacy in targeting both mutant and wild-type cells with high efficiency for NSCLC?"

The report directly addresses this:
- **Specific drug candidates**: 24 unique compounds are named with ChEMBL IDs, organized by drug class (EGFR, KRAS, ALK)
- **Both mutant and wild-type targeting**: Each drug class includes a "Dual-Target Evidence" subsection explaining how the drugs affect both mutant and wild-type cells
- **High efficiency**: The Discussion section (lines 229-241) provides a selectivity comparison table and cites pivotal trial efficacy data
- **NSCLC context**: Disease resolved to `EFO_0003060`, all drugs connected to NSCLC through Open Targets associations and clinical trials

The report also includes:
- Clinical recommendations table (line 265) mapping mutation status to drug choices
- Research gaps (pan-KRAS, combination strategies, predictive biomarkers)
- Limitations (toxicity, resistance, biomarker gaps)
- Knowledge graph structure for persistence

The report comprehensively answers the competency question. The template used is closest to Template 1 (Drug Discovery/Repurposing) which is appropriate for this CQ.

**Score: 9/10** -- The question is fully answered with specific drugs, mechanisms, and dual-target rationale.

---

## 10. Hallucination Risk -- MEDIUM

**High-confidence claims from tool outputs** (low risk):
- Gene CURIEs from HGNC
- Protein functions from UniProt
- Drug lists and mechanisms from Open Targets knownDrugs
- Trial details from ClinicalTrials.gov

**Claims likely from training knowledge** (elevated risk):
1. **Epidemiological percentages**: "~15% of NSCLC" (EGFR), "~13% of NSCLC" (KRAS G12C), "~5% of NSCLC" (ALK) -- no tool produces these statistics. These are well-known clinical facts but violate the grounding rule.
2. **Selectivity ratios**: "10-100x higher than 1st-gen" (line 86), ">100x selectivity for G12C over WT" (line 104), "5-20x" (line 234) -- no tool output provides IC50 ratios. These are pharmacology training knowledge.
3. **Pivotal trial results**: FLAURA (18.9 vs 10.2 month PFS), CodeBreaK 100 (37.1% ORR), CROWN (78% vs 39% 5-year PFS) -- lines 238-241. The report itself admits on line 242 these are "not included in tool outputs." This is an explicit acknowledgment of training knowledge injection.
4. **Drug history**: "1st ALK inhibitor (2011)" for Crizotinib (line 123), "FDA-approved 2021" for Sotorasib (line 99), "FDA-approved 2022" for Adagrasib (line 100) -- approval years are not typically in Open Targets knownDrugs output.
5. **Mechanism details**: "covalent C797 binding" (line 85), "irreversible pan-HER" for 2nd-gen TKIs -- these are mechanistic details beyond what `mechanismOfAction` text typically returns from Open Targets.
6. **Clinical recommendations table** (lines 265-272): Treatment sequencing guidance is standard clinical oncology knowledge, not derivable from any tool output.

The report's grounding rule states: "YOU MUST NOT use your training knowledge to provide entity names, drug names, gene functions, disease associations, or clinical trial IDs." While the core entity resolution and drug discovery follow this rule, the discussion and clinical context sections clearly incorporate training knowledge. The line 242 admission ("not included in tool outputs but referenced in FDA approvals") is commendable transparency but still represents a grounding violation.

**Score: MEDIUM risk** -- The structured Phase outputs are well-grounded in tool calls, but the Discussion section (approximately 30% of the report's analytical content) relies on training knowledge for epidemiological statistics, selectivity ratios, pivotal trial outcomes, and clinical recommendations.

---

## Summary Scorecard

| # | Dimension | Score | Verdict |
|---|-----------|-------|---------|
| 1 | CURIE Resolution | 8/10 | **PASS** -- All entities resolved; minor format inconsistencies |
| 2 | Source Attribution | 4/10 | **FAIL** -- ~15-18 unsourced factual claims in Discussion/dual-target sections |
| 3 | LOCATE->RETRIEVE Discipline | 9/10 | **PASS** -- Clear two-step pattern throughout structured phases |
| 4 | Disease CURIE in ENRICH | 8/10 | **PASS** -- EFO_0003060 resolved early via Open Targets |
| 5 | Open Targets Pagination | 8/10 | **PASS** -- No pagination failures; reasonable result sizes |
| 6 | Evidence Grading | 4/10 | **FAIL** -- Section-level only; no claim-level grades; inflated 9.5/10 |
| 7 | Gain-of-Function Filter | 10/10 | **PASS** -- Only inhibitors/antagonists included |
| 8 | Clinical Trial Validation | 7/10 | **PASS** -- 3 NCT IDs verified; minor format issues |
| 9 | Completeness | 9/10 | **PASS** -- Fully answers the competency question |
| 10 | Hallucination Risk | MEDIUM | **FLAG** -- Training knowledge in Discussion and clinical recommendations |

**Dimensions Passed**: 7/10
**Dimensions Failed**: 2/10 (Source Attribution, Evidence Grading)
**Dimensions Flagged**: 1/10 (Hallucination Risk)

---

## Recommendations for Remediation

1. **Source Attribution**: Every claim in the Discussion section (lines 217-284) needs either a `[Source: tool(param)]` citation or an explicit `[No data: inferred from training knowledge]` disclaimer. The epidemiological percentages (~15%, ~13%, ~5%), selectivity ratios, and pivotal trial outcomes should either be retrieved from tools (e.g., PubMed for trial results) or clearly marked as "contextual knowledge not from tool output."

2. **Claim-Level Evidence Grading**: Replace the section-level L4 grades with individual claim grades. For example:
   - "EGFR resolved to HGNC:3236" -- L4 (0.95, HGNC authoritative)
   - "G12C mutation ~13% of NSCLC" -- L0 (no tool source, training knowledge)
   - "Osimertinib CHEMBL3353410 is EGFR inhibitor Phase 4" -- L4 (0.95, Open Targets)
   
   Then compute the true median, which would likely be L3 (0.75-0.80), not L4 (0.95).

3. **NCT ID Format**: Standardize to bare `NCT03804580` format (no colon) per the skill's CURIE conventions.

4. **CURIE Format**: Fix `CHEMBL:CHEMBL203` to `CHEMBL:203` in the validation table. Fix `EFO_0003060` to `EFO:0003060` in the header.

5. **Discussion Grounding**: Either remove the pivotal trial results (FLAURA, CodeBreaK 100, CROWN) or retrieve them via `query_pubmed` tool calls and cite accordingly. The current approach of including them with an L4 grade while admitting they are not from tool outputs is contradictory.
